## Lucia Zanoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5642772/publications.pdf

Version: 2024-02-01

687363 580821 32 978 13 25 citations h-index g-index papers 32 32 32 1275 citing authors all docs docs citations times ranked

#	Article	IF	Citations
1	18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1601-1610.	6.4	204
2	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine () Tj ETQq0 0 0 rgBT Biochemically Recurrent Prostate Cancer. Journal of Urology, 2017, 197, 676-683.		2 10 Tf 50 70 165
3	Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 4-12.	6.4	119
4	18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse. Clinical Nuclear Medicine, 2015, 40, e386-e391.	1.3	118
5	18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. Clinical Genitourinary Cancer, 2014, 12, 106-110.	1.9	68
6	Imaging of Prostate Cancer Using Fluciclovine. PET Clinics, 2017, 12, 145-157.	3.0	46
7	[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imagingâ€"version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 579-591.	6.4	39
8	FDG PET/CT predictive role in follicular lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 864-871.	6.4	32
9	Imaging of Prostate Cancer Using Fluciclovine. Urologic Clinics of North America, 2018, 45, 489-502.	1.8	31
10	Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients. Nuclear Medicine Communications, 2015, 36, 1065-1075.	1.1	25
11	Consistency of FDG-PET Accuracy and Cost-Effectiveness in Initial Staging of Patients With Hodgkin Lymphoma Across Jurisdictions. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 314-320.	0.4	22
12	PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. Seminars in Nuclear Medicine, 2021, 51, 621-632.	4.6	17
13	18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas. Clinical Nuclear Medicine, 2015, 40, e399-e404.	1.3	16
14	Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. European Journal of Radiology, 2021, 141, 109793.	2.6	16
15	[18F]-FDG PET/CT for suspected lymphoma relapse in a patient with concomitant pneumococcal pneumonia during COVID-19 outbreak: unexpected SARS-Cov-2 co-infection despite double RT-PCR negativity. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2038-2039.	6.4	9
16	A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Future Oncology, 2018, 14, 1101-1115.	2.4	8
17	Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1661-1671.	6.4	8
18	Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological–immunological monitoring of EBV infection, prompt diagnosis and early treatment. Transplant Immunology, 2016, 34, 60-64.	1.2	7

#	Article	IF	CITATIONS
19	18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy. Annals of Nuclear Medicine, 2019, 33, 716-723.	2.2	7
20	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 390-409.	6.4	7
21	<sup>11</sup> C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. Current Radiopharmaceuticals, 2014, 7, 79-83.	0.8	5
22	The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. Cancers, 2021, 13, 1575.	3.7	4
23	Nuclear medicine in urological cancers: what is new?. Future Oncology, 2014, 10, 2061-2072.	2.4	3
24	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Oncology Letters, 2011, 2, 195-200.	1.8	1
25	The Wandering Mesenteric Lymph Node. Clinical Nuclear Medicine, 2017, 42, e253-e254.	1.3	1
26	FDG-PET in Lymphoma: Nuclear Medicine Perspective. PET Clinics, 2012, 7, 21-33.	3.0	0
27	Cholescintigraphic patterns in a IBS patient with postprandial diarrhea. Digestive and Liver Disease, 2018, 50, 720-721.	0.9	0
28	SeHCAT test for bile acid malabsorption: may "the old―become "the gold one―in the diagnostic burden of chronic diarrhea?. Clinical and Translational Imaging, 2021, 9, 177-180.	2.1	0
29	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. Blood, 2015, 126, 5009-5009.	1.4	0
30	FLT PET/CT-Guided Biopsy in the Evaluation of Cancer. , 2016, , 65-76.		0
31	New Radiopharmaceutical Markers for Metabolism and Receptor. , 2017, , 95-104.		0
32	Prostate cancer imaging and therapy. , 2018, , .		0